<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893061</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000635986</org_study_id>
    <secondary_id>COL-MNEMOSYNE</secondary_id>
    <secondary_id>2007-12</secondary_id>
    <secondary_id>INCA-RECF0899</secondary_id>
    <secondary_id>EUDRACT-2008-003620-32</secondary_id>
    <nct_id>NCT00893061</nct_id>
  </id_info>
  <brief_title>Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer</brief_title>
  <official_title>A Prospective, Randomized, Open-label, Multicenter Study Evaluating the Effects on Cognitive Functions of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Estrogen can cause the growth of breast cancer cells. Aromatase inhibitors, such&#xD;
      as letrozole, anastrozole, and exemestane, may fight breast cancer by lowering the amount of&#xD;
      estrogen the body makes. Hormone therapy, using tamoxifen citrate, may fight breast cancer by&#xD;
      blocking the use of estrogen by the tumor cells. It is not yet known whether aromatase&#xD;
      inhibitors or tamoxifen citrate have less effect on memory in patients receiving treatment&#xD;
      for breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying letrozole, anastrozole, or exemestane to&#xD;
      see how they effect memory compared with tamoxifen citrate in treating postmenopausal women&#xD;
      with breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate verbal episodic memory in patients with breast cancer after 6 months of&#xD;
           treatment with aromatase inhibitors (AI) vs tamoxifen citrate.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate cognitive functions of these patients at month 6 and 12 of treatment.&#xD;
&#xD;
        -  To evaluate the psychological and social impact on these patients at month 6 and 12 of&#xD;
           treatment.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral tamoxifen citrate once daily for 1 year in the absence of&#xD;
           disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Arm II: Patients receive an oral aromatase inhibitor (letrozole, anastrozole, or&#xD;
           exemestane) once daily for 1 year in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
      Patients undergo cognitive, psychological, social, and quality of life assessments every 6&#xD;
      months using the CDS scale, the Edinburgh Handedness Inventory, the Mini Mental Test, the&#xD;
      French version of the National Adult Reading Test, the Benton Visual Retention test, the&#xD;
      direct and indirect capacities of the WAIS-R, the WMS sequential visual-spatial capacity, the&#xD;
      dual task test, categorical and formal verbal fluency, the Trail making test, the Stroop&#xD;
      test, the Wisconsin Card Sorting test, the choice reaction time test, the sequential visual&#xD;
      spatial capacity, the HADS scale, IADL, and QLQ-C30 questionnaires.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in verbal episodic memory performance after 6 months of treatment, using the Rey Auditory Verbal Learning Test</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in other cognitive functions at 6 and 12 months of treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychological and social impact at 6 and 12 months of treatment, using the HADS scale and quality of life questionnaires (i.e., IADL and QLQ-C30)</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral tamoxifen citrate once daily for 1 year in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive an oral aromatase inhibitor (letrozole, anastrozole, or exemestane) once daily for 1 year in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exemestane</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
          -  Meets criteria for initiating adjuvant endocrine therapy&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Estrogen receptor- and/or progesterone receptor-positive disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Postmenopausal, defined as no menstruation for â‰¥ 1 year, confirmed by a measurement of&#xD;
             FSH and 17-beta-estradiol&#xD;
&#xD;
          -  Karnofsky performance status 80-100%&#xD;
&#xD;
          -  Native speaker of French&#xD;
&#xD;
          -  Beneficiary of a French Social Security insurance plan&#xD;
&#xD;
          -  No prior cognitive disorders&#xD;
&#xD;
          -  No depression or other confirmed active psychiatric disease&#xD;
&#xD;
          -  Able to undergo the medical monitoring of the trial due to geographic, social or&#xD;
             psychological reasons&#xD;
&#xD;
          -  No personal or family history of thromboembolic disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior adjuvant chemotherapy&#xD;
&#xD;
          -  No concurrent follow-up participation on another study&#xD;
&#xD;
          -  No concurrent treatment with psychotropic substances (i.e., long half life&#xD;
             benzodiazepines, antipsychotics, anticholinesterase)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie Le Rhun</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie Le Rhun</last_name>
      <phone>33-32-029-5959</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>May 2, 2009</study_first_submitted>
  <study_first_submitted_qc>May 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2009</study_first_posted>
  <last_update_submitted>January 20, 2011</last_update_submitted>
  <last_update_submitted_qc>January 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2011</last_update_posted>
  <keyword>stage IA breast cancer</keyword>
  <keyword>stage IB breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>estrogen receptor-positive breast cancer</keyword>
  <keyword>progesterone receptor-positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

